Anti-integrin αvβ6 antibodies are detected in about 90% of UC patients, and the results of basic research suggest that these autoantibodies themselves may be causing the disease
CrownBio is a leading contract research organization (CRO) in both the drug discovery and biomarker discovery arenas with a range of innovative product portfolios available across sites in Asia, th...
Agreements with CoMotion at the University of Washington and Dana-Farber Cancer Institute add new prostate cancer and lymphoma models to the world’s largest PDX collection
Crown Bioscience enhances its existing portfolio of humanized drug target models (HuGEMM™) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs.
CrownBio will leverage Jiangsu Qyun Bio-Pharmaceuticals expertise to support the Investigational New Drug Application (IND) and further clinical development of CrownBio’s proprietary 10B10 antibody.
The company is leveraging its material and polymer expertise to expand into the life sciences industry in the two major industry categories of bioprocessing and diagnostic and research products.
“With HuGEMM™, there is now a robust model system in place to enable scientists to assess the efficacy of human biologic therapeutics directly without resorting to mouse surrogates.”
2 of 3
Receive JSR Life Sciences news on your RSS reader.